Efpeglenatide is a long-acting agonist of the glucagon-like peptide-1 (GLP-1) receptor. Efpeglenatide improves insulin sensitivity, lowers blood glucose levels, and delays weight gain in diabetic and obese mouse models. Efpeglenatide has been applied in Type 2 diabetes research, providing an efficient experimental tool and preclinical evaluation value for developing metabolic disease intervention strategies, investigating weight loss mechanisms, and exploring insulin signaling regulation pathways.